This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental material
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pan, N. J.
Right arrow Articles by Goguen, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pan, N. J.
Right arrow Articles by Goguen, J. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2009, p. 385-392, Vol. 53, No. 2
0066-4804/09/$08.00+0     doi:10.1128/AAC.00670-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Targeting Type III Secretion in Yersinia pestis{triangledown} ,{dagger}

Ning J. Pan, Michael J. Brady, John M. Leong, and Jon D. Goguen*

Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Worcester, Massachusetts 01655

Received 21 May 2008/ Returned for modification 11 August 2008/ Accepted 30 October 2008

Yersinia pestis, the causative agent of plague, utilizes a plasmid-encoded type III secretion system (T3SS) to aid it with its resistance to host defenses. This system injects a set of effector proteins known as Yops (Yersinia outer proteins) into the cytosol of host cells that come into contact with the bacteria. T3SS is absolutely required for the virulence of Y. pestis, making it a potential target for new therapeutics. Using a novel and simple high-throughput screening method, we examined a diverse collection of chemical libraries for small molecules that inhibit type III secretion in Y. pestis. The primary screening of 70,966 compounds and mixtures yielded 421 presumptive inhibitors. We selected eight of these for further analysis in secondary assays. Four of the eight compounds effectively inhibited Yop secretion at micromolar concentrations. Interestingly, we observed differential inhibition among Yop species with some compounds. The compounds did not inhibit bacterial growth at the concentrations used in the inhibition assays. Three compounds protected HeLa cells from type III secretion-dependent cytotoxicity. Of the eight compounds examined in secondary assays, four show good promise as leads for structure-activity relationship studies. They are a diverse group, with each having a chemical scaffold not only distinct from each other but also distinct from previously described candidate type III secretion inhibitors.


* Corresponding author. Mailing address: Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655. Phone: (508) 856-2490. Fax: (508) 856-3355. E-mail: jon.goguen{at}umassmed.edu

{triangledown} Published ahead of print on 17 November 2008.

{dagger} Supplemental material for this article may be found at http://aac.asm.org/.


Antimicrobial Agents and Chemotherapy, February 2009, p. 385-392, Vol. 53, No. 2
0066-4804/09/$08.00+0     doi:10.1128/AAC.00670-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.